At a glance
Adult RSV Vaccinations Administered
In June 2023, the Advisory Committee on Immunization Practices (ACIP) voted to recommend that adults aged ≥60 years may receive a single dose of an RSV vaccine, using shared clinical decision-making. In June 2024, the ACIP voted to recommend a single dose of RSV vaccine for all adults 75 years and older and adults 60–74 years who are at increased risk for severe RSV disease.† On June 26, 2024, CDC adopted these recommendations. In April 2025, ACIP recommended that adults 50–59 years who are at increased risk for severe RSV disease were added to the previous recommendation. This recommendation was adopted by the HHS Secretary on June 25, 2025. The data below capture the number of RSV doses administered to adults 50 years and older.†
The projected pharmacy estimates are based on IQVIA‡,§ Longitudinal Prescription Claims (LRx) and vaccinations administered in retail pharmacies (including chain, mass merchandise, food stores, and independent pharmacies).± The projected physicians' medical offices estimates are based on IQVIA's Medical Claims (Dx).^
Vaccinations administered in workplaces, community locations, long-term care settings, and other medical settings such as public health clinics are not represented in these data.
- Figure 3. Weekly Cumulative Estimated Number of RSV Vaccinations Administered in Retail Pharmacies and Physicians' Medical Offices, Adults 50 Years and Older, United States*,†. Data Source(s): Data Source(s): IQVIA LRx and Dx.
*National estimates for retail pharmacies and physicians’ medical offices include vaccinations administered in 50 states and the District of Columbia. National estimates for medical office vaccinations do not include doses where geographic information (i.e. which state the dose was administered in) was missing. Pharmacy data are through Friday of each week and medical office data are through Saturday of each week. For data privacy, IQVIA calculates age based on year of birth and everyone born in a given year is assigned January 1 as their date of birth. The estimated cumulative number of doses administered to persons in eligible age groups should not be used to calculate vaccination coverage, since it does not necessarily reflect the persons eligible for ever having received RSV vaccination during the current season.
†CDC recommends a single dose of RSV vaccine for all adults 75 years and older and adults 50–74 years who are at increased risk for severed RSV disease (RSV Vaccines | RSV | CDC). We are not able to assess the presence of factors that increase risk of severe RSV in the IQVIA data; therefore, RSV vaccinations are included for adults ages 50–74 regardless of presence of any of these conditions. Each 2025-26 season week's estimate includes a total of 15,136,308 doses received by all adults 50 and older between August 12, 2023, through August 2, 2025. Estimates include Arexy and Abrysvo, recommended since June 2023, and mResvia, recommended since June 2024.
‡King, L. M., Bartoces, M., Fleming-Dutra, K. E., et al. (2020). Changes in US outpatient antibiotic prescriptions from 2011–2016. Clinical Infectious Diseases, 70(3), 370-377.
§McLaughlin, J. M., Swerdlow, D. L., Khan, F., et al. (2019). Disparities in uptake of 13-valent pneumococcal conjugate vaccine among older adults in the United States. Human vaccines & immunotherapeutics, 15(4), 841-849.
±Using the raw number of doses administered at a subset of retail pharmacies, IQVIA uses a proprietary projection methodology to estimate the projected number of vaccinations administered at all retail pharmacies. For the 2045-25 season, projected estimates are based on a subset of 42,173 pharmacies.The total number of retail pharmacies in the U.S. was estimated at 57,000 in 2022.The estimates include RSV vaccinations that were billed to insurers (i.e. claims) or paid by cash. Projected pharmacy estimates are updated each week for the prior 13 weeks but an initial evaluation has shown that the number of doses changed minimally over time. The retail pharmacy of the future | McKinsey. Accessed on 08.21.2025.
^Using the raw number of doses administered at the offices of a subset of physicians from American Medical Association's (AMA) proprietary list, IQVIA uses a proprietary projection methodology to estimate the projected number of vaccinations administered in medical offices of all physicians from AMA's list. For the 2024–25 season, projected estimates were based on a subset of 11,011 AMA office-based physicians who administered RSV vaccine. For context, for 2022–23, the number of office-based physicians in the U.S. is 691,382 (https://data.hrsa.gov/topics/health-workforce/nchwa/ahrf). The estimates include RSV vaccinations that are claims-based only, and estimates are expected to increase over time for a given time period as claims are processed and adjudicated. Projected estimates are updated monthly and do not mature until about two months. This results in an increase or decrease in the initial or subsequent estimates for a given week. Evaluation of changes in IQVIA flu vaccination estimates over time during the 2022–23 season is available and indicates that the reported number of doses administered for a particular week increased 10.7% over the next few weeks.